Soricimed Tests SOR-C13 in Texas
Sackville, N.B.-based biotech Soricimed Biopharma Inc. has signed a contract to conduct Phase I clinical trials at The University of Texas MD Anderson Cancer Center in Houston, Texas, meaning its drug candidate SOR-C13 will be tested at three North American facilities.
The drug has been in trials since last autumn at two Canadian facilities – the Juravinski Cancer Centre in Hamilton, Ont., and the nearby London Health Science Centre. In an interview yesterday, Chairman and Chief Scientific Officer Jack Stewart said the Phase I trials should take about a year.
SOR-C13 is a targeted